The Drug Controller General of India (DCGI) recently granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), making it the first dengue vaccine to be approved in the country.
About QDENGA (TAK-003):
It is a dengue vaccine developed by the Japanese pharmaceutical company Takeda.
It is the first dengue vaccine to be approved in India.
The vaccine has been approved for the prevention of dengue in individuals aged four to 60.
QDENGA is a live-attenuated (weakened) tetravalent vaccine designed to provide protection against all four dengue virus serotypes (DENV-1 to DENV-4).
It is administered as a two-dose regimen, with doses given three months apart.
The vaccine can be administered irrespective of whether an individual has had a previous dengue infection and does not require pre-vaccination screening.
The vaccine has already been approved in more than 40 countries, including the European Union, the United Kingdom, Brazil, Indonesia, and Argentina.
What is Dengue?
Dengue disease is a mosquito-borne tropical disease caused by the dengue virus, leading to mild, flu-like symptoms in most people.
However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage.
It poses a significant global public health threat, with prevalence in over 125 countries.
India accounts for nearly one-third of the global dengue burden.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
